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1. Introduction
Asthma is a common airway disease, affecting worldwide
a percentage of people between 1% and 18%. Although the
proper management of asthmatic patients should be ensured
by following international documents or guidelines (GL), e.g.
GINA (Global Initiative for Asthma), several evidences in litera-
ture show that they’re not always fully applied in daily clinical
practice, leading to a poor control of the disease. Furthermore,
one of the first causes of poor symptoms control is adherence
to therapy, drastically low in asthmatic patients than in other
diseases. Secondarily, the choice of therapeutic scheme could
be crucial for the control of the disease. With the evidence
that patients in GINA steps 1 and 2 may be at risk of serious
exacerbations, following the suggestion that an as need treat-
ment with SABA alone could increase the risk of serious
exacerbations, and that ICS use reduces that risk, in novel
GINA guidelines the use of as-needed therapy with ICS+for-
moterol has been added to treatment suggestions.
2. The burden of adherence
One of the main problems in the management of asthmatic
patients, regardless of the severity, type and therapeutic strategy
chosen, is adherence to treatment. In fact, it is well known that
adherence to prescribed therapies, in subjects suffering from
asthma, is very low, resulting in one of the principal causes of
poor control of the disease [1]. In order to overcome this problem,
in addition to an essential health education aimed to raise aware-
ness of the importance of therapy, some add-on devices have
been studied and tested tomonitor the frequency and the correct
way in which patients take their drugs.
3. Mild-moderate asthma
Mild asthma is a well-controlled asthma with step 1 or step 2
treatment, including as-needed therapy, usually SABA, low-dose
ICS, or antileukotrienes (LTRA) [1]. Some evidence assumed that
the poor control of symptoms in mild asthma could be principally
due to an inadequate treatment or a low compliance. Another
healthy burden in patients with mild asthma is the frequency of
exacerbations, reported as any change in lung function test or in
symptoms from the patient’s usual status [1].
3.1. Therapy in mild-moderate asthma
The first crucial step in the management of asthmatic patients is
the choice of the better therapy or therapeutic plan. The most
recent drafting of the GINA document, in the case of mild-
moderate patients at steps 1 and 2, offers to the clinician the
possibility to use different schemes, ranging from the use of an as-
needed therapy to a fixed therapy [1]. One of the most significant
changes, made in GINA 2019, is just in STEP 1 and 2, with the
possibility to choose between the novel therapeutic strategy with
a combination of inhaled corticosteroids/formoterol (ICS/
Formoterol) or the already existing as-needed short-acting beta
2 agonist (SABA) or low ICS dose therapy according to patient’s
step. The need for change stems from the fact that patients of the
first two GINA steps, despite the therapy, have frequent exacerba-
tions and 30-40% of them requiring emergency management [2].
Despite this, until the last version, GINA suggested only SABA as an
as-needed therapy with or without the additional chronic use of
low-dose ICS controllers for these patients. As previously men-
tioned, in this group of patients, generally poorly symptomatic or
asymptomatic, adherence to treatment, particularly ICS, is gener-
ally rather poor [1,3], resulting in an overuse of SABA, usually easily
accessible in pharmacies also without a medical prescription (i.e.
Italy, Spain, and UK for emergency access only) [3]. In addition, the
subjective perception of a rapid improvement in symptoms, after
SABA inhalation, can contribute to greater confidence in bronch-
odilator drugs [4]. Notwithstanding an unquestionable efficacy of
SABA, the overuse has been associated to an increased risk of poor
asthma control, exacerbations and in several cases also death [5],
principally because patients usually can preferentially use the as
need therapy rather than regular ICS or ICS/LABA, masking wor-
sening symptoms [6]. Therefore, preferred controller treatment in
GINA 2019, suggested at STEP 1, is the combination ICS/formo-
terol, prescribed also for as need strategy rather than SABA [1,4].
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The first study able to corroborate this choicewas SYGMA 1,where
3836 Step 2 GINA patients have been enrolled [7]. The investiga-
tors found that the as-needed budesonide/formoterol (BUD/FM)
combination was able to provide no less protection than the
maintenance regimen with BUD, and both therapeutic
approaches resulted to be better than the only as-needed terbuta-
line strategy [7]. The subsequent study called SYGMA 2, where
4176 asthmatic patients, once again belonging to the GINA Step 2,
were treated with placebo twice daily plus BUD/FM (200/6 μg) on
demand or with BUD twice daily plus SABA as needed for
52 weeks [3] demonstrated a non-inferiority of on-demand treat-
ment compared to continuous BUD, in asthma exacerbations rate,
although the on-demand formulation resulted worst in symptom
control [3] (Table 1). In the most recent Novel START study, 668
patients with mild asthma were recruited in three different treat-
ment arms: 1. SABA when needed; 2. BUD twice daily (BID) plus
SABA when needed; or 3. BUD/FM, as needed, treating them for
52 weeks. The rate of disease relapse was found to be lower in
patients treated with BUD/FM as needed, compared to those
treated with SABA and were no different from patients treated
with BUD BID. Despite this, maintenance treatment with BUD was
found to be superior to BUD/FM on demand in terms of asthma
symptoms [8] (Table 2). Finally, the variation in exacerbations
frequency has been sought also in a PRACTICAL trial, where 885
mild asthmatic patients received BUD/FM as needed or BUD
maintenance therapy, resulting in a higher reduction in exacerba-
tions rate in BUD/FM arm (0.119 vs 0.172; relative rate 0.69, 95% CI
0.48–1.00; p = 0.049) [9]. In addition, a recent study analyzing the
preferences of a cohort of patients enrolled in the Practical study
showed that they preferred as-needed combination therapy to
the maintenance BUD one, if they had experienced it [10]. Finally,
new observations lead to the question of how much the steroid
therapy can bemodulated in patients depending on the degree of
eosinophilic inflammation. A recent study published in NEJM,
where 295 patients were treated with tiotropium, mometasone,
or placebo, concludes that there was no substantial difference in
response to the two drugs in subjects with low eosinophilia in
sputum, laying the foundation for further studies to compare the
effect of ICS with other treatments in subjects with low eosino-
philia [11].
3.1.1. Long-term therapy with ICS, benefits
The steroids act by binding to a specific site at the intracyto-
plasmic receptor, which migrates to the nucleus and modu-
lates specific targeted gene transcription. As these drugs
directly affect the bronchial wall, several factors condition
the severity of side-effects. These factors include the condition
of the bronchial wall, the properties of the drug, the dosage
regimen, and the acceptability of the drug by the patient.
Various studies have been conducted to explore the risk–
benefit ratio of ICS in asthma. The inhaled corticosteroids
have been known to be effective in the control of the symp-
toms of asthma, bronchial inflammation, relapse of the disease
and occurrence of the inflammation of the bronchus after
discontinuation of the treatment. Furthermore, a report on
asthma deaths published by the College of Physicians of the
United Kingdom highlighted that among the most important
risk factors which can lead to asthma death, is the abuse of β
2-agonists and the nonuse of ICS maintenance therapy [12].
3.1.2. Long-term therapy with ICS, side effects
As previously described, ICS are considered to be themost effective
treatment for the management of persistent asthma due to their
anti-inflammatory effect. Although administered by inhalation, sev-
eral side effects have been reported in the chronic use of ICS, with
a direct relationship between systemic exposure, and therefore
dosage, and severity of effects. Controversial data exist on the
possibility that ICS affect growth in children with mild-to-
moderate asthma. Leonibus et al. [13] showed that ICS can act on
pubertal growth by determining a reduced final height in children
with asthma,with an effect proportional to the dosage taken by the
patient. A further meta-analysis, about data of 16 trials, demon-
strates that in ICS treated children there is a reduction of growth of
0.7% comparedwith not treated one [14]. The effect of ICS in adults
is less evident, some cases of variation in urinary cortisol secretion
are reported, while other articles do not report the same effect.
Table 1. Principal observations in SYGMA 1 and 2 study.
SYGMA 1 [7]
Group 1. Terbutaline as
needed


















CS need 27.0% 12.8% 14.6%
Adherence 79.0 ± 23.3% 79.0 ± 23.3% 78.9 ± 22.4%
Lung function test








Group 1. BUD/FM as needed Group 2. BUD maintenance
Exacerbations rate 0.11 0.11
Time to first exacerbation hazard ratio 0.96; 95% CI, 0.78 to 1.17
Symptoms control (ACQ-5) change from baseline − 0.35 − 0.46
difference 0.11 (95% CI, 0.07 to 0.15) p < 0.001
CS need (mean/SD) (daily inhaled glucocorticoid metered dose [μg]) 103.9 (109.6) 251.1 (117.7)
Lung function (FEV1 change from baseline) 104 ml 136.6 ml
difference −32.6 ml (95% CI, −53.7 to −11.4) p = 0.003
Adherence 64.0 ± 30.0% 62.8 ± 29.4%
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Other rare effects reported effects are impoverishment of bone
density, skin thinning, and bruising [15].
4. Therapy in severe asthma
Severe asthma deserves a separate mention and, also in this case,
the therapeutic approach is substantially changed. In GINA 2019
biological drugs are moved to first place in the case of
a therapeutic add-on need, downgrading OCS to a second choice.
In this case, GINA 2019 looks at the side effects of medium-
long term therapy with OCS, of which it is well known that
chronic use can lead to serious comorbidities (i.e. diabetes,
hypertension, osteoporosis) [16].
Biological drugs have also proven to be widely effective in
symptom control both in trials and in real life, in most
patients, and have a good safety profile, proving to be
a valid substitute for OCS in most cases.
5. Conclusion
In conclusion, the GINA 2019 document opens up to a greater
therapeutic choice in the first two steps, with the indication of
ICS/formoterol as the first choice therapy and as-needed
therapy in the first two Steps. In addition, in patients with
severe asthma, biological drugs have been indicated as the
first therapeutic choice, proving to be effective in many forms
of this disease, in order to reduce the use of systemic corti-
costeroids and their side effects.
6. Expert opinion
The therapeutic approach suggested by GINA 2019 provides
clinicians with an important opportunity in patient manage-
ment. By using the ICS/formoterol combination on demand,
compared to SABA alone, the intake of ICS is inevitably
increased, but with a limited risk of side effects, as described in
the dedicated paragraph, in favor of greater symptom control,
as demonstrated by the studies described in the text, therefore,
this approach seems to be more effective than SABA.
In GINA recommendation one of the crucial points is the
problem of the adherence, which is dramatically low in
asthma patients. Regardless of the type of therapeutic
approach and the molecules chosen by the clinicians, in the
management of asthmatic patients, the problem linked to
the fact that very often therapies are not taken, thus greatly
increasing the risk of exacerbations, must also be taken into
Table 2. Principal observation in Novel START and practical study.
NOVEL START Study [8]
Group 1. Albuterol as needed
Group 2. BUD maintenance
+ SABA as needed Group 3. BUD/FM as needed
Annualized Exacerbation Rate absolute rate, per patient,
per year Comparison with Gr.3, relative rate, (95% CI)
0.4000.49 (0.33–0.72) p < 0.001 0.1751.12
(0.70–1.79) p = 0.65
0.195-
Number of severe exacerbations Comparison with Gr.3,
relative risk, (95% CI)
230.40 (0.18–0.86) 210.44 (0.20–0.96) 9-
Number of patients withdrawn because of treatment
failure Comparison with Gr.3, mean difference, (95% CI)
370.33 (0.17–0.63) 220.56 (0.28–1.13) 12-
(ACQ-5) score difference across timepoints Comparison
with Gr.3, mean difference, (95% CI)
– 0.15 (−0.24 to −0.06) -+ 0.14 (0.05 to 0.23) –
FEV1% (L) difference across timepoints Comparison with
Gr.3, mean difference, (95% CI)
-0.03 L (−0.006 to 0.07) -0.004 L (−0.03 to 0.04) -
Geometric mean FeNO difference across time points
Comparison with Gr.3, mean difference, (95% CI)
-0.83 (0.75–0.91) -1.13 (1.02–1.25) –
BUD mean dose (±SD),- μg, per day NA 222 ± 113 107 ± 109




Group 1. BUD/FM as needed Group 2. BUD maintenance
+ terbutaline as needed
Severe asthma exacerbations (absolute rate per patient
per year)
0.119 0.172
Gr.1 vs Gr.2, relative rate, (95% CI) 0.69 (0.48–1.00) p = 0.049
Time to 1st severe exacerbation
Gr.1 vs Gr.2, hazard ratio, (95% CI)
0.60; (0.40–0.91) p = 0.015
Time to 1st severe or moderate exacerbation
Gr.1 vs Gr.2, hazard ratio, (95% CI)
0.59; (0.41–0.84) p = 0.004
Severe/Moderate asthma exacerbations (absolute rate per
patient per year) Gr.1 vs Gr.2, relative rate, (95% CI)
0.165 0.237
0.70 (0.51–0.95) p = 0.024
Number of patients withdrawn because of treatment
failure Gr.1 vs Gr.2, relative risk, (95% CI)
9 11
0.84; (0.35–2.00) p = 0.69
ACQ-5 score difference across timepoints Gr.1 vs Gr.2,
mean difference, (95% CI)
0.06; (−0.005 to 0.12) p = 0.69
FEV1% (L) difference across timepoints
Gr.1 vs Gr.2, mean difference, (95% CI)
0.006 L (−0.026 to 0.04) p = 0.69
FeNO geometric mean difference across timepoints
Gr.1 vs Gr.2, mean difference, (95% CI)
1.13; (1.07–1.21) p < 0.001
BUD mean dose Gr.1 vs Gr.2, daily inhaled budesonide
metered mean dose [μg], (95% CI)
−126.5 μg per day, (- 171.0 to – 81.9)
Overall mean adherence to twice-daily dose of BUD
maintenance therapy
NA 76%
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account. It is, therefore, necessary, during periodic visits, to
check the patient’s ability to take the drug and the real
adherence to the prescribed therapy. To overcome this pro-
blem, improve and monitor adherence to the therapy, the
use of devices to be connected to the devices should be
implemented, able to monitor the doses taken by the
patients and the quality of inhalation maneuvers, already in
study and in use in some protocols.
Another time, with the goal to reduce the burden of the poor
adherence of patients to a low ICS dose therapy, GINA 2019
purpose the possibility of replacing low dosage ICS with ICS/FM
as needed. In this case, in the trials mentioned in the text, we have
seen how sometimes a similar effectiveness and sometimes
a better result is demonstrated in the use of the ICS/FM combina-
tion rather than BUD maintenance alone. Despite this, we believe
that the choice of one therapy rather than another should be
carefully evaluated on a case-by-case basis and choosing the
most appropriate molecules also based on the clinical-biological
characteristics of the patients (i.e. eosinophilia). In any case, further
studies would be necessary.
The last important changes, dedicated to step 5, respond to
the need to reduce the use of OCS in asthmatic subjects. The
important well-known side effects related to the chronic use
of corticosteroids (i.e. cataract, osteoporosis, diabetes, hyper-
tension, increased susceptibility to infections) are a serious
burden both from a clinical and economic point of view and
therefore must be reduced. The data, coming from both clin-
ical trials and real life, regarding the effects of monoclonal
antibodies are extremely positive and consequently, we
believe it’s important, in these patients, to research biological
and clinical parameters in order to use more and more biolo-
gical drugs instead of OCS.
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